Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

MDX-210 bispecific antibody targeting HER-2/neu protein on cancer cells: Began a Phase I/II trial in combination with AMGN's Neupogen G-CSF, in 45 patients to e

WIR Staff
June 12, 1995 7:00 AM UTC

Medarex Inc. (MEDX), Annandale, N.J. Amgen Inc. (AMGN), Thousand Oaks, Calif. Product: MDX-210 bispecific antibody targeting HER-2/neu protein on cancer cells, joined to a trigger antibody that sign...